Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392.SH) announced that its wholly-owned subsidiary, Xiamen Wantai Canghai Biotech Co., Ltd., has received a clinical trial approval notice from the National Medical Products Administration for its recombinant trivalent rotavirus subunit vaccine (E. coli). The approval permits the initiation of clinical trials aimed at preventing rotavirus gastroenteritis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments